P. Chapman, A. Hauschild, C. Robert, J. Haanen, P. Ascierto et al., Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, New England Journal of Medicine, vol.364, issue.26, pp.2507-2523, 2011.
DOI : 10.1056/NEJMoa1103782

K. Flaherty, I. Puzanov, K. Kim, A. Ribas, G. Mcarthur et al., Inhibition of Mutated, Activated BRAF in Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.9, pp.809-828, 2010.
DOI : 10.1056/NEJMoa1002011
URL : http://europepmc.org/articles/pmc3724529?pdf=render

C. Robert, B. Karaszewska, J. Schachter, P. Rutkowski, A. Mackiewicz et al., Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib, New England Journal of Medicine, vol.372, issue.1, pp.30-39, 2015.
DOI : 10.1056/NEJMoa1412690
URL : http://www.zora.uzh.ch/id/eprint/107163/1/Robert%20C%20et%20al.%20-%20N%20Engl%20J%20Med%202014.pdf

G. Long, D. Stroyakovskiy, H. Gogas, E. Levchenko, F. De-braud et al., Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial, The Lancet, vol.386, issue.9992, pp.444-51, 2015.
DOI : 10.1016/S0140-6736(15)60898-4

J. Larkin, P. Ascierto, B. Dreno, V. Atkinson, G. Liszkay et al., -Mutated Melanoma, New England Journal of Medicine, vol.371, issue.20, pp.1867-76, 2014.
DOI : 10.1056/NEJMoa1408868

M. Fleischhacker and B. Schmidt, Circulating nucleic acids (CNAs) and cancer???A survey, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol.1775, issue.1, pp.181-232, 2007.
DOI : 10.1016/j.bbcan.2006.10.001

C. Alix?panabieres, H. Schwarzenbach, and K. Pantel, Circulating Tumor Cells and Circulating Tumor DNA, Annual Review of Medicine, vol.63, issue.1, pp.199-215, 2012.
DOI : 10.1146/annurev-med-062310-094219
URL : https://hal.archives-ouvertes.fr/hal-01793403

H. Schwarzenbach, D. Hoon, and K. Pantel, Cell-free nucleic acids as biomarkers in cancer patients, Nature Reviews Cancer, vol.61, issue.83, pp.426-463, 2011.
DOI : 10.3322/caac.20107

S. Tsao, J. Weiss, C. Hudson, C. Christophi, J. Cebon et al., Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations, Scientific Reports, vol.29, issue.1, p.11198, 2015.
DOI : 10.1097/DAD.0b013e3181584950

M. Saint?jean, G. Quereux, J. Nguyen, L. Peuvrel, A. Brocard et al., Younger age at the time of first metastasis in BRAF-mutated compared to BRAF wild-type melanoma patients, Oncology Reports, vol.32, issue.2, pp.808-822, 2014.
DOI : 10.3892/or.2014.3265

A. Knol, A. Vallee, G. Herbreteau, J. Nguyen, E. Varey et al., Clinical significance of BRAF mutation status in circulating tumor DNA of metastatic melanoma patients at baseline, Experimental Dermatology, vol.22, issue.10, pp.783-791, 2016.
DOI : 10.1158/1078-0432.CCR-15-1031
URL : https://hal.archives-ouvertes.fr/inserm-01408920

E. Eisenhauer, P. Therasse, J. Bogaerts, L. Schwartz, D. Sargent et al., New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2, pp.228-275, 2009.
DOI : 10.1016/j.ejca.2008.10.026

M. Schreuer, G. Meersseman, S. Van-den-herrewegen, Y. Jansen, I. Chevolet et al., Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors, Journal of Translational Medicine, vol.24, issue.6, p.95, 2016.
DOI : 10.1038/cr.2014.44

M. Sanmamed, S. Fernandez?landazuri, C. Rodriguez, R. Zarate, M. Lozano et al., Quantitative Cell-Free Circulating BRAFV600E Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors, Clinical Chemistry, vol.61, issue.1, pp.297-304, 2015.
DOI : 10.1373/clinchem.2014.230235

A. Marchetti, J. Palma, L. Felicioni, D. Pas, T. Chiari et al., Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients, Journal of Thoracic Oncology, vol.10, issue.10, pp.1437-1480, 2015.
DOI : 10.1097/JTO.0000000000000643

A. Vallee, C. Audigier?valette, G. Herbreteau, J. Merrien, L. Tessonnier et al., Rapid clearance of circulating tumor DNA during treatment with AZD9291 of a lung cancer patient presenting the resistance EGFR T790M mutation, Lung Cancer, vol.91, pp.73-77, 2016.
DOI : 10.1016/j.lungcan.2015.11.008

A. Sacher, C. Paweletz, S. Dahlberg, R. Alden, O. Connell et al., Mutations in Advanced Lung Cancer, JAMA Oncology, vol.2, issue.8, pp.1014-1036, 2016.
DOI : 10.1001/jamaoncol.2016.0173

A. Santiago?walker, R. Gagnon, J. Mazumdar, M. Casey, G. Long et al., Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials, Clinical Cancer Research, vol.22, issue.3, pp.567-74, 2016.
DOI : 10.1158/1078-0432.CCR-15-0321